Scarica l'app Stockscreener
430.88
0.80%
-3.9217
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MDGL Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$434.80
Aprire:
$434.5
Volume 24 ore:
48,431
Relative Volume:
0.15
Capitalizzazione di mercato:
$9.87B
Reddito:
-
Utile/perdita netta:
$-518.67M
Rapporto P/E:
-17.15
EPS:
-25.12
Flusso di cassa netto:
$-438.32M
1 W Prestazione:
-3.26%
1M Prestazione:
-6.92%
6M Prestazione:
-0.36%
1 anno Prestazione:
+24.20%
Intervallo 1D:
$429.73
$444.43
Intervallo di 1 settimana:
$416.21
$444.43
Portata 52W:
$265.00
$615.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Nome
Madrigal Pharmaceuticals Inc
Settore
Industria
Telefono
404-380-9263
Indirizzo
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
434.55 | 9.87B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.18 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.05 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
731.68 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.49 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
295.38 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Iniziato | Barclays | Overweight |
| 2026-01-06 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-11-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2025-11-03 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2025-10-15 | Iniziato | Truist | Buy |
| 2025-09-04 | Ripresa | H.C. Wainwright | Buy |
| 2025-02-28 | Aggiornamento | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | Reiterato | H.C. Wainwright | Buy |
| 2024-06-28 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-06-11 | Iniziato | Wolfe Research | Outperform |
| 2024-04-22 | Iniziato | BofA Securities | Underperform |
| 2024-03-15 | Aggiornamento | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | Iniziato | Citigroup | Buy |
| 2024-02-26 | Downgrade | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | Reiterato | Oppenheimer | Outperform |
| 2022-12-19 | Reiterato | H.C. Wainwright | Buy |
| 2022-12-19 | Reiterato | Piper Sandler | Overweight |
| 2022-12-19 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-08-06 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | Ripresa | Goldman | Buy |
| 2020-11-24 | Ripresa | Evercore ISI | Outperform |
| 2020-11-06 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-31 | Iniziato | Piper Sandler | Overweight |
| 2020-06-05 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-05-05 | Iniziato | Chardan Capital Markets | Buy |
| 2020-01-30 | Iniziato | Canaccord Genuity | Buy |
| 2020-01-09 | Aggiornamento | UBS | Neutral → Buy |
| 2019-11-07 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-25 | Iniziato | Stifel | Hold |
| 2019-06-10 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-22 | Iniziato | SVB Leerink | Outperform |
| 2019-01-23 | Iniziato | UBS | Neutral |
| 2018-12-14 | Iniziato | Wolfe Research | Outperform |
| 2018-12-12 | Iniziato | B. Riley FBR | Neutral |
| 2018-11-19 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2018-09-04 | Iniziato | Citigroup | Buy |
| 2018-08-06 | Downgrade | Goldman | Buy → Neutral |
| 2018-06-28 | Iniziato | Raymond James | Mkt Perform |
Mostra tutto
Madrigal Pharmaceuticals Inc Borsa (MDGL) Ultime notizie
Segall Bryant & Hamill LLC Invests $10.32 Million in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Weakness - simplywall.st
Madrigal Pharmaceuticals: How Noninvasive Data Is Powering a Smarter Clinical Strategy! - Smartkarma
Madrigal Pharmaceuticals, Inc. $MDGL Shares Sold by TD Asset Management Inc - MarketBeat
MDGL: Rezdiffra's growth accelerates with a broad pipeline and strong 2026 financial outlook - TradingView
Intech Investment Management LLC Lowers Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals (MDGL) Reports Record 2025 Revenue Driven by Rezdiffra Success - Finviz
Madrigal Pharmaceuticals EVP Dier sells $505k in shares By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals (NASDAQ:MDGL) CFO Mardi Dier Sells 1,183 Shares - MarketBeat
Madrigal Pharmaceuticals (MDGL) director sale notice: 1,183 shares after RSU vest - Stock Titan
MADRIGAL PHARMACEUTICALS EVP and CFO Sells Shares to Cover Tax Obligations - TradingView
Madrigal (MDGL) CFO has shares sold automatically for tax withholding - Stock Titan
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: Exploring a 54% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Rafferty Asset Management LLC Lowers Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
JPMorgan Chase & Co. Reduces Stake in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
William Blair Investment Management LLC Has $188.88 Million Stock Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Artisan Partners Limited Partnership Acquires 4,683 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Q4 earnings miss, MASH drug sales drive top line, stock down - MSN
MDGL SEC FilingsMadrigal Pharmac 10-K, 10-Q, 8-K Forms - Stock Titan
Fox Run Management L.L.C. Takes $1.06 Million Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Why Madrigal Pharmaceuticals (MDGL) Is Down 9.7% After Rezdiffra’s Near US$1 Billion Debut Year - Yahoo Finance
Exit Recap: Will Madrigal Pharmaceuticals Inc outperform during market ralliesEarnings Summary Report & Weekly Setup with High ROI Potential - baoquankhu1.vn
Madrigal: The Easiest Money May Have Been Made (NASDAQ:MDGL) - Seeking Alpha
Director exercises 2,500 Madrigal (MDGL) options at $7.36 - Stock Titan
Madrigal Pharmaceuticals Reports 2025 Financial Results - MyChesCo
Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference - The Manila Times
Madrigal Grants Inducement Awards to Five Employees - MyChesCo
Madrigal (MDGL) Q4 2025 Earnings Call Transcript - The Globe and Mail
A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Rezdiffra’s First Full Year Near US$1b In Sales - simplywall.st
Madrigal Pharmaceuticals, Inc. (MDGL): Investor Outlook Reveals 53% Potential Upside In Biotechnology - DirectorsTalk Interviews
Vanguard Group Inc. Sells 65,227 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal’s Rezdiffra Breakthrough Spurs MASH Pipeline Growth And Valuation Debate - Yahoo Finance
MASH Drugs Market to hit US$ 929.05 Million by 2033 | North America - openPR.com
Madrigal Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Benzinga
Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down - Bitget
Is now the right time to enter Madrigal Pharmaceuticals Inc.July 2025 Opening Moves & Safe Entry Momentum Tips - mfd.ru
MDGL: B of A Securities Maintains Neutral Rating, Lowers Price T - GuruFocus
Bank of America Issues Pessimistic Forecast for Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Price - MarketBeat
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q4 2025 Earnings Call Transcript - Insider Monkey
Fiera Capital Corp Lowers Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal inks licensing deal with China’s Suzhou Ribo for MASH drugs - MSN
Decoding Madrigal Pharmaceuticals Inc (MDGL): A Strategic SWOT I - GuruFocus
Madrigal Pharma earnings missed by $1.97, revenue topped estimates - Investing.com Canada
Madrigal Eyes MASH Future As Rezdiffra Nears Blockbuster Revenue - Citeline News & Insights
Earnings call transcript: Madrigal Pharmaceuticals Q4 2025 misses EPS, stock dips - Investing.com India
Madrigal Pharmaceuticals Inc (MDGL) Q4 2025 Earnings Call Highlights: Record Sales and ... By GuruFocus - Investing.com Canada
Madrigal Pharmaceuticals Inc (MDGL) Q4 2025 Earnings Call Highli - GuruFocus
Madrigal Pharmaceuticals (NASDAQ:MDGL) Posts Quarterly Earnings Results, Misses Estimates By $2.61 EPS - MarketBeat
Madrigal Pharmaceuticals, Inc. reports strong Rezdiffra sales growth in Q4 2025; first full year of launch approaches $1 billion in net sales - AlphaStreet News
Madrigal Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Madrigal Pharmaceuticals (MDGL) Reports Strong Q4 2025 Performan - GuruFocus
Madrigal Pharmaceuticals Inc Azioni (MDGL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):